NASDAQ:MRKR Marker Therapeutics (MRKR) Stock Price, News & Analysis $0.88 -0.06 (-6.80%) As of 11:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Marker Therapeutics Stock (NASDAQ:MRKR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Marker Therapeutics alerts:Sign Up Key Stats Today's Range$0.81▼$0.9250-Day Range$0.94▼$1.9252-Week Range$0.81▼$5.95Volume1.01 million shsAverage Volume822,368 shsMarket Capitalization$11.34 millionP/E RatioN/ADividend YieldN/APrice Target$13.17Consensus RatingStrong Buy Company Overview Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas. Read More Marker Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreMRKR MarketRank™: Marker Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 305th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingStrong Buy Consensus RatingMarker Therapeutics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMarker Therapeutics has received no research coverage in the past 90 days.Read more about Marker Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Marker Therapeutics are expected to decrease in the coming year, from ($0.65) to ($2.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Marker Therapeutics is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Marker Therapeutics is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMarker Therapeutics has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Marker Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.37% of the float of Marker Therapeutics has been sold short.Short Interest Ratio / Days to CoverMarker Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marker Therapeutics has recently increased by 387.97%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMarker Therapeutics does not currently pay a dividend.Dividend GrowthMarker Therapeutics does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-0.75 Percentage of Shares Shorted6.37% of the float of Marker Therapeutics has been sold short.Short Interest Ratio / Days to CoverMarker Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marker Therapeutics has recently increased by 387.97%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News Sentiment0.07 News SentimentMarker Therapeutics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Marker Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for MRKR on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Marker Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Marker Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.80% of the stock of Marker Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 22.39% of the stock of Marker Therapeutics is held by institutions.Read more about Marker Therapeutics' insider trading history. Receive MRKR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRKR Stock News HeadlinesMarker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference4 hours ago | globenewswire.comMarker Therapeutics (MRKR) Falls 20.6% After Positive Clinical StudyAugust 27 at 12:11 PM | insidermonkey.comChase, Bank of America, Wells Fargo Preparing for BIG ChangeThanks to this brand-new law #S.1582 signed by President Trump… Jeff Brown believes the largest banks in America could soon begin to replace every single dollar in your bank account… With a better, more technologically advanced dollar… Potentially making a lot of people rich in the process.August 28 at 2:00 AM | Brownstone Research (Ad)Marker Therapeutics stock soars on promising Phase 1 lymphoma study dataAugust 26 at 7:35 PM | investing.comMarker Therapeutics provides update on observations from Phase 1 APOLLO studyAugust 26 at 7:35 PM | msn.comMarker Therapeutics Stock Drops After Report About Lymphoma TreatmentAugust 26 at 12:34 PM | benzinga.comMarker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed LymphomaAugust 26 at 7:00 AM | globenewswire.comMarker Therapeutics (NASDAQ:MRKR) Raised to "Sell" at Wall Street ZenAugust 19, 2025 | americanbankingnews.comSee More Headlines MRKR Stock Analysis - Frequently Asked Questions How have MRKR shares performed this year? Marker Therapeutics' stock was trading at $3.11 at the beginning of 2025. Since then, MRKR shares have decreased by 71.7% and is now trading at $0.8790. How were Marker Therapeutics' earnings last quarter? Marker Therapeutics, Inc. (NASDAQ:MRKR) announced its quarterly earnings results on Thursday, August, 14th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.26. The firm had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.72 million. Marker Therapeutics had a negative net margin of 271.12% and a negative trailing twelve-month return on equity of 114.59%. Who are Marker Therapeutics' major shareholders? Marker Therapeutics' top institutional shareholders include Jane Street Group LLC (0.19%). View institutional ownership trends. How do I buy shares of Marker Therapeutics? Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Marker Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Marker Therapeutics investors own include SCYNEXIS (SCYX), Tesla (TSLA), Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA), Viking Therapeutics (VKTX) and OPKO Health (OPK). Company Calendar Last Earnings8/14/2025Today8/28/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRKR CIK1094038 Webwww.markertherapeutics.com Phone(713) 400-6400FaxN/AEmployees60Year Founded2018Price Target and Rating Average Price Target for Marker Therapeutics$13.17 High Price Target$19.00 Low Price Target$8.00 Potential Upside/Downside+1,300.7%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.73 million Net Margins-271.12% Pretax Margin-270.17% Return on Equity-114.59% Return on Assets-90.31% Debt Debt-to-Equity RatioN/A Current Ratio3.45 Quick Ratio3.45 Sales & Book Value Annual Sales$6.59 million Price / Sales1.85 Cash FlowN/A Price / Cash FlowN/A Book Value$0.81 per share Price / Book1.16Miscellaneous Outstanding Shares12,940,000Free Float11,930,000Market Cap$12.16 million OptionableNot Optionable Beta1.45 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:MRKR) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.